KPV 500MCG (100 CT.)

KPV 500MCG is a tripeptide consisting of the amino acid sequence lysine-proline-valine, derived from the C-terminal region of alpha-melanocyte-stimulating hormone (alpha-MSH). This naturally occurring peptide fragment has attracted significant research interest due to its observed bioactivity in studies examining inflammatory signaling pathways, mucosal immunology, and innate immune cell modulation. In laboratory settings, KPV has been studied for its effects on NF-kB nuclear translocation, a key event in the inflammatory transcriptional program, with in vitro studies in colonic epithelial cell lines and macrophage cultures demonstrating measurable modulation of this pathway upon KPV exposure at defined concentrations.
Researchers have also investigated interactions of KPV with melanocortin receptor subtypes, particularly MC1R, which is expressed on immune cells and plays a role in the regulation of cytokine production and immune cell activation states. Published studies have explored effects on the expression of pro-inflammatory mediators including interleukin-1 beta, tumor necrosis factor-alpha, and inducible nitric oxide synthase in cellular models of inflammation. The small molecular weight of KPV (approximately 342 Da) makes it amenable to various delivery system studies, including nanoparticle encapsulation and hydrogel incorporation research in drug delivery science.

VOLUME:100 ct.

FDA DISCLAIMER

The information provided on this website has not been evaluated by the U.S. Food and Drug Administration (FDA). None of the statements herein, nor any of the products offered, are intended to diagnose, treat, cure, or prevent any medical condition.

All products are supplied strictly as laboratory research reagents and are not for human consumption. We do not provide products to patients and do not make any claims regarding medical use.

Coffee & Pepper Peptides operates solely as a chemical supplier. It is not a compounding pharmacy and does not operate as a compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act.